Details
Stereochemistry | RACEMIC |
Molecular Formula | C19H17Cl3N2S.HNO3 |
Molecular Weight | 474.789 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O[N+]([O-])=O.ClC1=CC=C(CCC(CN2C=CN=C2)SC3=C(Cl)C=CC=C3Cl)C=C1
InChI
InChIKey=ZHPWRQIPPNZNML-UHFFFAOYSA-N
InChI=1S/C19H17Cl3N2S.HNO3/c20-15-7-4-14(5-8-15)6-9-16(12-24-11-10-23-13-24)25-19-17(21)2-1-3-18(19)22;2-1(3)4/h1-5,7-8,10-11,13,16H,6,9,12H2;(H,2,3,4)
Butoconazole, trade names Gynazole-1, an imidazole antifungal used in gynecology for the local treatment of vulvovaginal candidiasis (infections caused by Candida). The exact mechanism of the antifungal action of butoconazole nitrate is unknown; however, it is presumed to function as other imidazole derivatives via inhibition of steroid synthesis. Imidazoles generally inhibit the conversion of lanosterol to ergosterol, resulting in a change in fungal cell membrane lipid composition. This structural change alters cell permeability and, ultimately, results in the osmotic disruption or growth inhibition of the fungal cell.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1780 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2184984 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | GYNAZOLE-1 Approved UseGynazole·1® (butoconazole nitrate) vaginal cream, 2% is indicated for the local treatment of vulvovaginal candidiasis (infections caused by Candida). The diagnosis should be confirmed by KOH smears and/or cultures. Launch Date2012 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4471.25 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24939312 |
100 mg single, vaginal dose: 100 mg route of administration: Vaginal experiment type: SINGLE co-administered: |
BUTOCONAZOLE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
0.895 ng/mL |
0.05 g single, vaginal dose: 0.05 g route of administration: Vaginal experiment type: SINGLE co-administered: |
BUTOCONAZOLE unknown | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
1.74 ng/mL |
0.1 g single, vaginal dose: 0.1 g route of administration: Vaginal experiment type: SINGLE co-administered: |
BUTOCONAZOLE unknown | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
113290.135 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24939312 |
100 mg single, vaginal dose: 100 mg route of administration: Vaginal experiment type: SINGLE co-administered: |
BUTOCONAZOLE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
36.38 ng × h/mL |
0.05 g single, vaginal dose: 0.05 g route of administration: Vaginal experiment type: SINGLE co-administered: |
BUTOCONAZOLE unknown | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
73.48 ng × h/mL |
0.1 g single, vaginal dose: 0.1 g route of administration: Vaginal experiment type: SINGLE co-administered: |
BUTOCONAZOLE unknown | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
17.834 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24939312 |
100 mg single, vaginal dose: 100 mg route of administration: Vaginal experiment type: SINGLE co-administered: |
BUTOCONAZOLE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
5 g 1 times / day single, vaginal Recommended Dose: 5 g, 1 times / day Route: vaginal Route: single Dose: 5 g, 1 times / day Sources: |
unknown, adult n = 314 Health Status: unknown Age Group: adult Sex: M+F Population Size: 314 Sources: |
Disc. AE: Vaginal pain or burning, Abdominal pain... AEs leading to discontinuation/dose reduction: Vaginal pain or burning Sources: Abdominal pain Cramp |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Abdominal pain | Disc. AE | 5 g 1 times / day single, vaginal Recommended Dose: 5 g, 1 times / day Route: vaginal Route: single Dose: 5 g, 1 times / day Sources: |
unknown, adult n = 314 Health Status: unknown Age Group: adult Sex: M+F Population Size: 314 Sources: |
Cramp | Disc. AE | 5 g 1 times / day single, vaginal Recommended Dose: 5 g, 1 times / day Route: vaginal Route: single Dose: 5 g, 1 times / day Sources: |
unknown, adult n = 314 Health Status: unknown Age Group: adult Sex: M+F Population Size: 314 Sources: |
Vaginal pain or burning | Disc. AE | 5 g 1 times / day single, vaginal Recommended Dose: 5 g, 1 times / day Route: vaginal Route: single Dose: 5 g, 1 times / day Sources: |
unknown, adult n = 314 Health Status: unknown Age Group: adult Sex: M+F Population Size: 314 Sources: |
Sample Use Guides
The recommended dose of Gynazole·1 (butoconazole nitrate) is one applicatorful of cream (approximately 5 grams of the cream) intravaginally. This amount of cream contains approximately 100 mg of butoconazole nitrate.
Route of Administration:
Vaginal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1495832
Increasing levels of butoconazole were added to 150 microliters of a dilution in Roiron medium adjusted to 50,000 Trichomonas/ml. Results were read after 1, 2, 6 and 24 hours aerobic incubation at 37 degrees C. Minimum lethal concentration was 93 micrograms/microliters after one hour, 23 micrograms/microliter after six hours and 12 micrograms/microliters after 24 hours. These findings warrant in vivo studies of butoconazole against Trichomonas. This drug may prove very useful since concomitant infection of the genital tract by Trichomonas and Candida is common.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C514
Created by
admin on Fri Dec 15 18:59:54 GMT 2023 , Edited by admin on Fri Dec 15 18:59:54 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
64872-77-1
Created by
admin on Fri Dec 15 18:59:53 GMT 2023 , Edited by admin on Fri Dec 15 18:59:53 GMT 2023
|
PRIMARY | |||
|
CHEMBL1295
Created by
admin on Fri Dec 15 18:59:53 GMT 2023 , Edited by admin on Fri Dec 15 18:59:53 GMT 2023
|
PRIMARY | |||
|
47471
Created by
admin on Fri Dec 15 18:59:54 GMT 2023 , Edited by admin on Fri Dec 15 18:59:54 GMT 2023
|
PRIMARY | |||
|
C47427
Created by
admin on Fri Dec 15 18:59:54 GMT 2023 , Edited by admin on Fri Dec 15 18:59:54 GMT 2023
|
PRIMARY | |||
|
47464
Created by
admin on Fri Dec 15 18:59:54 GMT 2023 , Edited by admin on Fri Dec 15 18:59:54 GMT 2023
|
PRIMARY | RxNorm | ||
|
DB00639
Created by
admin on Fri Dec 15 18:59:53 GMT 2023 , Edited by admin on Fri Dec 15 18:59:53 GMT 2023
|
PRIMARY | |||
|
DTXSID6045452
Created by
admin on Fri Dec 15 18:59:53 GMT 2023 , Edited by admin on Fri Dec 15 18:59:53 GMT 2023
|
PRIMARY | |||
|
100000084860
Created by
admin on Fri Dec 15 18:59:54 GMT 2023 , Edited by admin on Fri Dec 15 18:59:54 GMT 2023
|
PRIMARY | |||
|
4805237NP5
Created by
admin on Fri Dec 15 18:59:53 GMT 2023 , Edited by admin on Fri Dec 15 18:59:53 GMT 2023
|
PRIMARY | |||
|
4805237NP5
Created by
admin on Fri Dec 15 18:59:53 GMT 2023 , Edited by admin on Fri Dec 15 18:59:53 GMT 2023
|
PRIMARY | |||
|
1082300
Created by
admin on Fri Dec 15 18:59:54 GMT 2023 , Edited by admin on Fri Dec 15 18:59:54 GMT 2023
|
PRIMARY | |||
|
m2801
Created by
admin on Fri Dec 15 18:59:53 GMT 2023 , Edited by admin on Fri Dec 15 18:59:53 GMT 2023
|
PRIMARY | Merck Index | ||
|
3241
Created by
admin on Fri Dec 15 18:59:53 GMT 2023 , Edited by admin on Fri Dec 15 18:59:53 GMT 2023
|
PRIMARY | |||
|
SUB00918MIG
Created by
admin on Fri Dec 15 18:59:53 GMT 2023 , Edited by admin on Fri Dec 15 18:59:53 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD